treatment of overactive bladder articles & resources on Made-in-China.com

AltheRx Pharmaceuticals Has Received a Notice of Allowance for Its Patent Application

Oct 21, 2013

US-based clinical development firm AltheRx Pharmaceuticals has received a notice of allowance for its patent application from the US Patent and Trademark Office (USPTO) for the use of solabegron in combination with antimuscarinics at both ...

Tags: Solabegron Combination Therapy, Oab Patients

Watson Laboratories Received FDA Approval for Its ANDA of Trospium Chloride Capsules

Dec 4, 2012

Watson Laboratories, a subsidiary of Watson Pharmaceuticals, has received FDA approval for its abbreviated new drug application (ANDA) of Trospium Chloride Extended-release Capsules. Watson anticipates beginning the shipment of the ...

Tags: FDA, Trospium Chloride Extended-release Capsules, pharmaceutical product

Mylan Have Signed a Settlement Agreement with Pfizer

Nov 29, 2012

Mylan and its subsidiary, Mylan Pharmaceuticals, have signed a settlement agreement with Pfizer, Pharmacia & Upjohn Company and Pfizer Health related to Detrol LA patent litigation. The litigation is related to Mylan Pharmaceuticals' ...

Tags: Detrol LA patent litigation, drug application

Antares and Watson Pharmaceuticals Have Introduced Gelnique 3% Gel 3%

Nov 28, 2012

Antares Pharma and Watson Pharmaceuticals have introduced Gelnique 3% (oxybutynin) gel 3%, for the treatment of overactive bladder (OAB). The product is available in a metered pump dispenser and is delivered transdermally, resulting in a ...

Tags: Gelnique 3%, treatment of overactive bladder, urology

Myrbetriq Is a Once Daily Oral Beta-3 Adrenergic Agonist Discovered and Developed

Jun 4, 2012

Astellas Pharma has gained FDA approval for Myrbetriq (mirabegron) extended-release tablets for the treatment of overactive bladder (OAB) with symptoms of urge urinary incontinence, urgency and urinary frequency. Myrbetriq is a once ...

Tags: FDA approval, pharmaceutical product, oral OAB treatment

Watson Pharmaceuticals Confirmed Favorable US District Court

Apr 5, 2012

Watson Pharmaceuticals has confirmed favorable US District Court for the District of Delaware ruling in generic Sanctura XR (trospium chloride extended-release capsules) patent suit. The Court has ruled that the asserted claims of US ...

Tags: treatment of overactive bladder, pharmaceutical product

treatment of overactive bladder